{"id":735157,"date":"2025-03-10T09:24:01","date_gmt":"2025-03-10T09:24:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=735157"},"modified":"2025-03-10T09:24:01","modified_gmt":"2025-03-10T09:24:01","slug":"her2-gastric-cancer-market-to-witness-upsurge-in-growth-during-the-forecast-period-20242034-examine-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/her2-gastric-cancer-market-to-witness-upsurge-in-growth-during-the-forecast-period-20242034-examine-delveinsight_735157.html","title":{"rendered":"HER2+ Gastric Cancer Market to Witness Upsurge in Growth During the Forecast Period (2024-2034), Examine DelveInsight"},"content":{"rendered":"
\"HER2+<\/a><\/div>\n
Key HER2+ Gastric Cancer companies in the market include – Roche, Elevar Therapeutic, Bristol-Myers Squibb, Merck, Daiichi Sankyo Inc., Genentech, Bayer\/Loxo Oncology, Eli Lilly and Company, Remegen Biosciences, AstraZeneca, Hutchison Medipharma Limited, Jiangsu Alphamab Biopharmaceuticals, MacroGenics\/Zai Lab, Merck Sharp & Dohme Corp., Merus N.V., OncXerna Therapeutics, Inc., Innovent Biologics, and others.<\/div>\n

The HER2+ Gastric Cancer market is projected to grow significantly in the 7MM, which includes the United States, EU4—Germany, France, Italy, and Spain—the United Kingdom, and Japan. This growth is attributed to several factors, including the increasing incidence of HER2+ Gastric Cancer, advances in research and development, and innovations in the treatment landscape by various key HER2+ Gastric Cancer companies such as Roche, Elevar Therapeutic, Bristol-Myers Squibb, Merck, Daiichi Sankyo Inc., Genentech, Bayer\/Loxo Oncology, Eli Lilly and Company, Remegen Biosciences, AstraZeneca, Hutchison Medipharma Limited, Jiangsu Alphamab Biopharmaceuticals, LintonPharm, Qilu Pharmaceutical Co., Ltd., Shanghai Henlius Biotech, Bristol-Myers Squibb, Jiangsu HengRui Medicine, Seagen, MacroGenics\/Zai Lab, Merck Sharp & Dohme Corp., Merus N.V., OncXerna Therapeutics, Inc., Innovent Biologics, and others.<\/strong><\/p>\n

 <\/p>\n

DelveInsight’s latest report, “HER2+ Gastric Cancer Market Insight, Epidemiology And Market Forecast – 2034<\/a>”<\/strong>, provides an in-depth analysis of the evolving treatment landscape, epidemiological trends, and market dynamics across the 7MM. The report highlights advancements in HER2-targeted therapies, immunotherapy combinations, and antibody-drug conjugates (ADCs) that are poised to transform patient outcomes in this aggressive cancer subtype.<\/p>\n

 <\/p>\n

Download the report to understand which factors are driving the HER2 Positive Gastric Cancer therapeutic market @ HER2 Positive Gastric Cancer Market Trends<\/a>.<\/strong><\/p>\n

 <\/p>\n

The gastric cancer incidence varies considerably across different geographic regions, with Eastern Asian countries, including Japan, reporting the highest incidence rates. The US also accounts for a notable proportion of gastric cancer cases, representing 1.5% of all new cancer diagnoses each year.<\/p>\n

 <\/p>\n

As per DelveInsight’s estimates, the HER2+ gastric cancer market is projected to grow significantly from 2024 to 2034. This growth is driven by a rising incidence, improved diagnostic protocols, and expanding therapeutic options. Several pipeline drugs for HER2+ gastric cancer, including Evorpacept (ALX Oncology), Zanidatamab (Jazz Pharmaceuticals), IAM1363 (Iambic Therapeutics), ELVN 002 (Enliven Therapeutics), ARX788 (Ambrx), and Rilvegostomig (AstraZeneca),<\/strong><\/em> are in development.<\/p>\n

 <\/p>\n

Discover evolving trends in HER2+ Gastric Cancer patient pool forecasts @ HER2+ Gastric Cancer Epidemiology Analysis<\/a>.<\/strong><\/p>\n

 <\/p>\n

Additionally, recent therapy approvals such as ENHERTU (Daiichi Sankyo and AstraZeneca), OPDIVO (Bristol Myers Squibb), trastuzumab (Roche), KEYTRUDA (Merck & Co., Inc.), and AIDIXI (RemeGen)<\/strong> <\/em>are further fueling the market growth. The FDA has also approved HLX02 (Henlius Biotech), a HERCEPTIN biosimilar, as an adjuvant therapy for patients with HER2-overexpressing metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma.<\/p>\n

Despite the active landscape of HER2+ gastric cancer therapeutics, there is a continued need for the development of novel drugs that are more effective and less toxic. DelveInsight’s leading oncology consultant notes, “One of the major challenges in treating HER2-positive gastric cancer is the development of resistance to existing therapies. It is indicated that up to 70% of patients who progress after the initial trastuzumab treatment may lose HER2 expression or acquire genetic alterations that render them resistant to further anti-HER2 therapies.” This underscores the potential impact of emerging therapies in revolutionizing HER2-positive gastric cancer treatment.<\/p>\n

 <\/p>\n

Unlock which emerging HER2+ gastric cancer drug is expected to capture the largest market share in 7MM by 2034. Visit the HER2+ gastric cancer Market Insights<\/a>.<\/strong><\/p>\n

 <\/p>\n

Recent developments, such as the US FDA’s Breakthrough Therapy designation given to Zanidatamab in November 2024 and significant clinical trial updates for Evorpacept, highlight the momentum in the field.<\/p>\n

In summary, the factors mentioned above are contributing to the significant expansion of the HER2+ gastric cancer market, suggesting a future where improved screening, innovative drug delivery systems, and novel therapies will transform the management of a disease that continues to challenge clinicians and patients alike.<\/p>\n

 <\/p>\n

Table of Contents<\/strong><\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
\n

1.<\/p>\n<\/td>\n

\n

Key Insights<\/p>\n<\/td>\n<\/tr>\n

\n

2.<\/p>\n<\/td>\n

\n

Executive Summary of HER2+ Gastric Cancer<\/p>\n<\/td>\n<\/tr>\n

\n

3.<\/p>\n<\/td>\n

\n

HER2+ Gastric Cancer Competitive Intelligence Analysis<\/p>\n<\/td>\n<\/tr>\n

\n

4.<\/p>\n<\/td>\n

\n

HER2+ Gastric Cancer: Market Overview at a Glance<\/p>\n<\/td>\n<\/tr>\n

\n

5.<\/p>\n<\/td>\n

\n

HER2+ Gastric Cancer: Disease Background and Overview<\/p>\n<\/td>\n<\/tr>\n

\n

6.<\/p>\n<\/td>\n

\n

Patient Journey<\/p>\n<\/td>\n<\/tr>\n

\n

7.<\/p>\n<\/td>\n

\n

HER2+ Gastric Cancer Epidemiology and Patient Population<\/p>\n<\/td>\n<\/tr>\n

\n

8.<\/p>\n<\/td>\n

\n

Treatment Algorithm, Current Treatment, and Medical Practices<\/p>\n<\/td>\n<\/tr>\n

\n

9.<\/p>\n<\/td>\n

\n

HER2+ Gastric Cancer Unmet Needs<\/p>\n<\/td>\n<\/tr>\n

\n

10.<\/p>\n<\/td>\n

\n

Key Endpoints of HER2+ Gastric Cancer Treatment<\/p>\n<\/td>\n<\/tr>\n

\n

11.<\/p>\n<\/td>\n

\n

HER2+ Gastric Cancer Marketed Products<\/p>\n<\/td>\n<\/tr>\n

\n

12.<\/p>\n<\/td>\n

\n

HER2+ Gastric Cancer Emerging Therapies<\/p>\n<\/td>\n<\/tr>\n

\n

13.<\/p>\n<\/td>\n

\n

HER2+ Gastric Cancer: Seven Major Market Analysis<\/p>\n<\/td>\n<\/tr>\n

\n

14.<\/p>\n<\/td>\n

\n

Attribute analysis<\/p>\n<\/td>\n<\/tr>\n

\n

15.<\/p>\n<\/td>\n

\n

7MM: Market Outlook<\/p>\n<\/td>\n<\/tr>\n

\n

16.<\/p>\n<\/td>\n

\n

Access and Reimbursement Overview of HER2+ Gastric Cancer<\/p>\n<\/td>\n<\/tr>\n

\n

17.<\/p>\n<\/td>\n

\n

KOL Views<\/p>\n<\/td>\n<\/tr>\n

\n

18.<\/p>\n<\/td>\n

\n

HER2+ Gastric Cancer Market Drivers<\/p>\n<\/td>\n<\/tr>\n

\n

19.<\/p>\n<\/td>\n

\n

HER2+ Gastric Cancer Market Barriers<\/p>\n<\/td>\n<\/tr>\n

\n

20.<\/p>\n<\/td>\n

\n

Appendix<\/p>\n<\/td>\n<\/tr>\n

\n

21.<\/p>\n<\/td>\n

\n

DelveInsight Capabilities<\/p>\n<\/td>\n<\/tr>\n

\n

22.<\/p>\n<\/td>\n

\n

Disclaimer<\/p>\n<\/td>\n<\/tr>\n

\n

23.<\/p>\n<\/td>\n

\n

About DelveInsight<\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

 <\/p>\n

Related Reports<\/strong><\/p>\n

HER2 Positive Gastric Cancer Pipeline Insight<\/a><\/strong><\/p>\n

HER2 Positive Gastric Cancer Pipeline Insight provides comprehensive insights about the HER2 Positive Gastric Cancer pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the HER2 Positive Gastric Cancer companies, including Jiangsu HengRui Medicine Co., Ltd., Pieris Pharmaceuticals, BioInvent International, Daiichi Sankyo|AstraZeneca, Shanghai JMT-Bio Inc., Acepodia Biotech, Inc., Klus Pharma Inc., Carisma Therapeutics Inc, Novartis Pharmaceuticals, Celularity Incorporated, Hoffmann-La Roche, DualityBio Inc., Shanghai Miracogen Inc., Bavarian Nordic, among others.<\/p>\n

 <\/p>\n

About DelveInsight<\/strong><\/p>\n

DelveInsight is a leading business Healthcare consultancy and market research firm specializing in life sciences. It assists pharmaceutical companies by offering comprehensive, end-to-end solutions to improve their performance<\/p>\n

Media Contact<\/span>
Company Name:<\/strong> DelveInsight Business Research LLP<\/a>
Contact Person:<\/strong> Arpit Anand
Email:<\/strong> Send Email<\/a>
Phone:<\/strong> +14699457679
Address:<\/strong>304 S. Jones Blvd #2432
City:<\/strong> Las Vegas
State:<\/strong> Nevada
Country:<\/strong> United States
Website:<\/strong> https:\/\/www.delveinsight.com\/consulting\/due-diligence-services<\/a><\/p>\n

\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

Key HER2+ Gastric Cancer companies in the market include – Roche, Elevar Therapeutic, Bristol-Myers Squibb, Merck, Daiichi Sankyo Inc., Genentech, Bayer\/Loxo Oncology, Eli Lilly and Company, Remegen Biosciences, AstraZeneca, Hutchison Medipharma Limited, Jiangsu Alphamab Biopharmaceuticals, MacroGenics\/Zai Lab, Merck Sharp & … Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,405,417,406,423],"tags":[],"class_list":["post-735157","post","type-post","status-publish","format-standard","hentry","category-Business","category-Health-Medicine","category-Marketing-Sales","category-Pharmaceuticals-Biotech","category-Professional-Services"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/735157","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=735157"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/735157\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=735157"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=735157"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=735157"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}